Can-Fite BioPharma Ltd.
CANF
Rank in Stocks
#31430
Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical... Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical firm dedicated to developing small molecule therapeutic agents. Its research and development efforts are concentrated on addressing conditions such as cancer, various liver inflammatory diseases, and erectile dysfunction. The company's lead investigational compound, Piclidenoson, has progressed through successful completion of its Phase III clinical trial for psoriasis and a Phase II clinical trial for COVID-19. Another promising candidate, Namodenoson, is presently undergoing a Phase III trial for hepatocellular carcinoma and a Phase IIb trial for non-alcoholic steatohepatitis. Furthermore, CF602 is in its pre-clinical phase, with potential application for erectile dysfunction. Beyond drug development, Can-Fite also creates a commercial predictive biomarker blood test kit specifically for A3AR. The company maintains strategic partnerships, including a licensing and collaboration agreement with CMS Medical for the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. A separate collaborative venture with Univo Pharmaceuticals focuses on identifying and jointly developing specific cannabis component formulations intended for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Founded in 1994 as Can-Fite Technologies Ltd., the company rebranded to Can-Fite BioPharma Ltd. in January 2001, and operates from its headquarters in Petah Tikva, Israel.
Share Price
$0.82125069
Last synced: 2026-11-11
Market Cap
$3.05M
Change (1 day)
-4.17%
Change (1 year)
-91.18%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Can-Fite BioPharma Ltd. (CANF)
Category
Healthcare
EPS for Can-Fite BioPharma Ltd. (CANF)
EPS as of June 2026 TTM: $-3.54
According to Can-Fite BioPharma Ltd.'s latest financial reports, its current EPS (TTM) is $-3.54. At the end of 2025 the company had an EPS of $-6.46, a decrease compared to its 2024 EPS of 0.00.
EPS history for Can-Fite BioPharma Ltd. from 2010 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-3.54 | -45.20% |
| 2025 | $-6.46 | 179,344.44% |
| 2024 | 0.00 | -40.00% |
| 2023 | $-0.01 | -52.00% |
| 2022 | $-0.01 | -58.33% |
| 2021 | $-0.03 | -29.08% |
| 2020 | $-0.04 | -71.80% |
| 2019 | $-0.15 | -11.76% |
| 2018 | $-0.17 | -10.53% |
| 2017 | $-0.19 | -36.67% |
| 2016 | $-0.30 | 11.11% |
| 2015 | $-0.27 | -22.86% |
| 2014 | $-0.35 | -42.62% |
| 2013 | $-0.61 | 8.93% |
| 2012 | $-0.56 | -22.22% |
| 2011 | $-0.72 | 71.43% |
| 2010 | $-0.42 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $-0.99 | -72.03% |
US
|
|
| $15.66 | -542.37% |
US
|
|
| $-7.07 | 99.72% |
US
|
|
| $-5.29 | 49.44% |
AU
|
|
| $12.88 | -463.84% |
BE
|
Questions about Can-Fite BioPharma Ltd.'s earnings per share (EPS)
What is Can-Fite BioPharma Ltd.'s earnings per share (EPS)?
Can-Fite BioPharma Ltd.'s earnings per share (EPS) over the last twelve months is $-3.54, as of Jun 2026.
What was Can-Fite BioPharma Ltd.'s earnings per share (EPS) in 2025?
In 2025, Can-Fite BioPharma Ltd.'s earnings per share (EPS) was $-6.46, compared with 0.00 in 2024.
How has Can-Fite BioPharma Ltd.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Can-Fite BioPharma Ltd.'s earnings per share (EPS) was highest in 2024 (0.00) and lowest in 2025 ($-6.46).
How does Can-Fite BioPharma Ltd.'s earnings per share (EPS) compare with similar companies?
Can-Fite BioPharma Ltd.'s earnings per share (EPS) ($-3.54) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.